$30.87+1.3%Nov 13 close
Figures through September 30, 2026, from the 10-Q filed November 4, 2026
Just reported
From Viridian Therapeutics, Inc.'s results release of November 4, 2026; its quarterly report has since been filed.
Actual
$25.8M
-64% y/y
Guided
—
No guide given
Actual
-$103.5M
Guided
—
No guide given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $25.8M | $70.6M | -63.51% |
| Profit | -$101.2M | -$34.6M | -192.52% |
| Free Cash Flow | -$93.1M | -$84.7M | -9.92% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Viridian Therapeutics, Inc. reported on November 4, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“We are highly encouraged by the strength of Lumvoa’s early launch in TED, which has exceeded expectations,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Viridian Therapeutics is a biotechnology company dedicated to developing better medicines for patients with autoimmune and rare diseases. Utilizing our expertise in antibody discovery and protein engineering, we aim to build on proven science to develop innovative medicines that address unmet needs and improve patient outcomes. With an immediate focus in thyroid eye disease (TED), we developed Lumvoa TM , a full IGF-1R antagonist approved by the U.S. FDA for the treatment of thyroid eye disease. We are also advancing elegrobart, a late-stage investigational subcutaneous therapy designed to further address unmet needs in TED and improve patient convenience. Beyond TED, we are advancing a pipeline of potential best-in-class medicines to address multiple serious autoimmune diseases. Viridian is based in Waltham, Massachusetts.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Viridian Therapeutics, Inc.’s Item 2.02 8-K filed November 4, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.